A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
← catalyst calendarNCT06452771 · readout in 107 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
59actual
Sites
1
Country
New Zealand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-27 | actual | When the study began enrolling |
| Primary completion | 2026-12-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-04 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers With Hyperlipidemia
Interventions
- Drug: ALN-ANG3
- Drug: Placebo (PB)
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events (TEAEs)
measured Up to Approximately 323 Days
Severity of TEAEs
measured Up to Approximately 323 Days
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed